EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study

Erwin Lankes, Levin Wiebelt, Kathrin Bettina Helge, Dirk Schnabel, Peter Kühnen, Oliver Blankenstein, Uta Neumann

Frontiers in Endocrinology · 07.07.2026 · 17

DOI: 10.3389/fendo.2026.1854737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 07.07.2026. Verfasst von Erwin Lankes und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology and Diabetology, Charité - Universitätsmedizin Berlin, ENDO-ERN Center, Berlin, Germany. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Hydrocortisone. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité-Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Replacement therapy for congenital adrenal hyperplasia (CAH) in childhood includes hydrocortisone and, in salt-wasting forms, addition of fludrocortisone. Immediate-release hydrocortisone often fails to adequately suppress early morning 17-hydroxyprogesterone (17OHP) levels. Hydrocortisone modified-release capsules (HMRC, Efmody ® ) were approved by the EMA in 2021 for the treatment of patients aged ≥12 years with CAH. This study evaluates the efficacy and safety of HMRC in children and adolescents based on real-world data collected from the I-CAH registry.

Methods

A single-center retrospective analysis of children with CAH was conducted. Linear mixed models (LMMs) were used to calculate pre–post comparisons of 17OHP saliva profiles, growth rate, bone age, body mass index, hydrocortisone and fludrocortisone dosage, blood pressure, and safety parameters before and during HMRC therapy (study registration, https://drks.de/search/de , DRKS00038319).

Findings

The median age of the 36 children with CAH at the time of treatment switching to HMRC was 10 years (interquartile range [IQR]: 8–14 years). Of these, 15 were prepubertal and 21 were (post)pubertal. HMRC therapy was associated with a deceleration of previously increased growth velocity (pre-switch: 0.1 SDS/year, 95% CI: 0.0 to 0.2; post-switch: -0.1 SDS/year, 95% CI: –0.2 to 0.1) and with a reduction of median difference of bone age and chronological age by 0.50 years (IQR -1.17–0.27, range -2.2–2.00). Mean hydrocortisone dose increased by 2.4 mg/m²/day during HMRC treatment. Mean morning 17OHP concentrations significantly decreased from 337 ng/L (95% CI: 240–437) to 214 ng/L (95% CI: 155–294) after switching to HMRC treatment. No adrenal crisis was observed.

Interpretation

Twice-daily HMRC therapy can also improve CAH therapy in children and adolescents in terms of hormonal control and growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalHydrocortisoneHumansChildRetrospective StudiesAdolescentFemaleMaleRegistriesDelayed-Action Preparations17-alpha-HydroxyprogesteroneChild, PreschoolHormone Replacement TherapyTreatment OutcomeFludrocortisone

Stichwörter der Autor:innen

17-hydroxyprogesteronechildrencongenital adrenal hyperplasiadisease-controlgrowthhydrocortisone modified-release capsulestreatment

Substanzen

HydrocortisoneDelayed-Action Preparations17-alpha-HydroxyprogesteroneFludrocortisone

Autor:innen und Institutionen

  • Department of Pediatric Endocrinology and Diabetology, Charité - Universitätsmedizin Berlin, ENDO-ERN Center, Berlin, Germany.
  • Center for Chronic Sick Children, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • German Center for Child and Adolescent Health (DZKJ), Partner Site Berlin, Berlin, Germany.

Förderung

  • Charité-Universitätsmedizin Berlin

Zitieren

APA

Lankes, E., Wiebelt, L., Helge, K. B., Schnabel, D., Kühnen, P., Blankenstein, O., & Neumann, U. (2026). Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1854737

Vancouver

Lankes E, Wiebelt L, Helge KB, Schnabel D, Kühnen P, Blankenstein O, et al. Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1854737

BibTeX
@article{Lankes2026,
  author = {Lankes, Erwin and Wiebelt, Levin and Helge, Kathrin Bettina and Schnabel, Dirk and Kühnen, Peter and Blankenstein, Oliver and Neumann, Uta},
  title = {Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fendo.2026.1854737}
}
Kostenlos starten →